Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) beat the analysts on revenue within the second quarter of 2025 however missed on income. Non-GAAP earnings per share was $0.66, above the analysts’ forecast of $0.62 and the corporate has raised its annual web revenue steerage for 2025 for the second time this yr. Teva expects annual earnings per share of $2.50-2.65, up from the underside vary of $2.45. There is no such thing as a change within the income steerage of $16.8-17.2 billion, up 3% from 2024. Income within the second quarter was $4.2 billion, unchanged from the corresponding quarter final yr.
RELATED ARTICLES
GAAP web revenue within the second quarter was $282 million in contrast with a loss within the corresponding quarter. Non-GAAP web revenue was $769 million within the second quarter, up 10.3% from the corresponding quarter.
Throughout the second quarter worldwide rankings businesses Moody’s and Fitch raised Teva’s credit standing, not but prime funding degree, however near it. Teva recycled debt by elevating a $2.3 billion bond and utilizing it to purchase again bonds due for compensation between 2026 and 2029. On the finish of the second quarter, Teva’s debt was $17.2 billion, down fr4om 2024 however up from the tip of the primary quarter.
Teva CEO Richard Francis mentioned, “Teva’s efficiency this quarter stands as a testomony to the distinctive energy of our modern portfolio, which stays the first engine driving our income development. Our key modern merchandise delivered a 26% improve in native forex, demonstrating their impression on our monetary trajectory and worth to sufferers. As we execute our Pivot to Progress technique, our give attention to innovation is unwavering, putting us firmly on monitor to realize a 30% working revenue margin by 2027. The speedy development of our transformation applications is already unlocking ~$140 million in annual run-rate financial savings in 2025, a crucial milestone towards our total ~$700 million web financial savings goal by 2027.”
He added, “Whereas our relentless dedication to advancing our modern portfolio now actually units Teva aside, our generics enterprise continues to offer a secure basis regardless of headwinds. The momentum behind our OTC merchandise and biosimilars, along with our present portfolio and pipeline, reinforce our ambition to double biosimilars’ revenues by 2027.”
Printed by Globes, Israel enterprise information – en.globes.co.il – on July 30, 2025.
© Copyright of Globes Writer Itonut (1983) Ltd., 2025.
